GERMAN drug developer BioNTech has signed an agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) to manufacture ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths worldwide ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

NHS England is set to introduce a pioneering liquid biopsy blood test, offering new hope to lung and breast cancer ...

Helena Yu, MD, discusses the efficacy of zipalertinib for EGFR-mutant non–small cell lung cancer and the importance of exploring therapies with CNS penetration in this space.

England's NHS pioneers a revolutionary blood test for faster cancer diagnosis and treatment. This 'liquid biopsy' detects ...

A new "liquid biopsy" test can help fast-track lung cancer patients to receive targeted therapy up to two weeks earlier, ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

The envisioned flow cytometry test will help to predict patient response to immunotherapies for five cancer indications.